ENVISIA THERAPEUTICS, INC.

Profile

Company Names

ENVISIA THERAPEUTICS, INC.

Addresses

419 DAVIS DRIVE, SUITE 100, MORRISVILLE, NC 27560

Phone Numbers

919.973.1440

 

Entity Type:

CORPORATION

Industry:

BIOTECHNOLOGY

Year Incorporated:

2013

State Incorporated:

DELAWARE

Total Amount Raised:

$14,717,521.00

Number of Funding Rounds:

2
Investment Rounds
Round #
Round Open Date
Amount Raised
Total Round Size
Amount Remaining to be Raised
Securities
2
2016-03-11 
$10,117,521.00 
$16,547,948.00 
$6,430,427.00 
Equity 
1
2015-10-01 
$4,600,000.00 
$5,115,354.00 
$515,354.00 
Debt 
People
First Name
Middle Name
Last Name
Titles
Related Companies
STEPHEN 
 
BLOCH 
DIRECTOR
VIACOR INC   |  MARINUS PHARMACEUTICALS INC   |  LIQUIDIA TECHNOLOGIES INC   |  DICOM GRID INC   |  AXIAL EXCHANGE, INC.   |  ENVISIA THERAPEUTICS INC.   |  LQ3 PHARMACEUTICALS, INC.   |  ENVISIA THERAPEUTICS, INC.   |  SAMPLE6, INC.   |  GENOME MEDICAL HOLDING CO   |  CORVIUM, INC.   |  ONKOS SURGICAL, INC.   |  EVOLVEIMMUNE THERAPEUTICS HOLDING COMPANY, LLC   |  IANTREK, INC.   |  LIQUIDIA CORP   |  ALLYX THERAPEUTICS, INC.   |  THYRON PHARMACEUTICALS, INC.
NEAL 
 
FOWLER 
DIRECTOR
LIQUIDIA TECHNOLOGIES INC   |  ENVISIA THERAPEUTICS INC.   |  LQ3 PHARMACEUTICALS, INC.   |  ENVISIA THERAPEUTICS, INC.
ADRIENNE 
 
GRAVES 
DIRECTOR
OCCULOGIX, INC.   |  AERPIO THERAPEUTICS, INC.   |  ENCORE VISION, INC.   |  TEARLAB CORP   |  ENVISIA THERAPEUTICS, INC.   |  SURFACE PHARMACEUTICALS, INC.   |  GREENBROOK TMS INC.   |  THEROPTIX, INC.   |  SURFACE OPHTHALMICS, INC.   |  OPUS GENETICS INC.   |  JELLISEE OPHTHALMICS INC.   |  QLARIS BIO, INC.
ERIC 
 
LINSLEY 
EXECUTIVE OFFICER
BAROSENSE INC   |  CEQUENT PHARMACEUTICALS INC   |  MILESTONE PHARMACEUTICALS INC.   |  ENVISIA THERAPEUTICS, INC.   |  CEREIUS, INC.
ED 
 
MATHERS 
DIRECTOR
LIQUIDIA TECHNOLOGIES INC   |  INTARCIA THERAPEUTICS, INC   |  ENVISIA THERAPEUTICS INC.   |  SYNLOGIC, INC.   |  MIRNA THERAPEUTICS, INC.   |  AMPLYX PHARMACEUTICALS, INC.   |  ENVISIA THERAPEUTICS, INC.   |  SYNLOGIC, LLC   |  TREVI THERAPEUTICS, INC.   |  AKOUOS, INC.   |  RENEO PHARMACEUTICALS, INC.   |  SENTI BIOSCIENCES, INC.   |  MIRUM PHARMACEUTICALS, INC.   |  CURZION PHARMACEUTICALS, INC.
GARY 
 
PHILLIPS 
DIRECTOR
DEBT ACQUISITION ASSOCIATES III, LLC   |  ALDEXA THERAPEUTICS, INC.   |  ALDEYRA THERAPEUTICS, INC.   |  GLOBAL COOLING, INC.   |  ENVISIA THERAPEUTICS, INC.   |  AMLI-ALLIANZ DAVIE REIT, LP   |  AMLI-ALLIANZ 1400 HI LINE DRIVE REIT, LP   |  TRITON CONSOLIDATED, INC.   |  1800 M STREET REIT, LP   |  FOREFRONT SOLUTIONS, INC.   |  AKMAZO CAPITAL FUND I, L.P.   |  AKMAZO CO-INVESTMENT A, LLC
SETH 
 
RUDNICK 
DIRECTOR
VAXINNATE CORP   |  LIQUIDIA TECHNOLOGIES INC   |  ENVISIA THERAPEUTICS INC.   |  G1 THERAPEUTICS, INC.   |  LQ3 PHARMACEUTICALS, INC.   |  MERYX INC.   |  ENVISIA THERAPEUTICS, INC.   |  ALTESA BIOSCIENCES, INC.
WILLIAM 
 
YELLE 
DIRECTOR
ALDEA PHARMACEUTICALS, INC.   |  ENVISIA THERAPEUTICS, INC.
BEN 
 
YERXA 
EXECUTIVE OFFICER
ENVISIA THERAPEUTICS, INC.
Filings
Filing Date
Filing Type
Source URL
Industry Classifier
Detailed Industry
Revenue Range
Securities
First Sale Date
2016-03-17
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2016-03-11 
2015-10-19
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Debt 
2015-10-01 
Brokers
Broker Dealer
Broker CRD#
Recipient Name
Recipient CRD#